Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

A new randomized controlled trial out of the Baker Heart and Diabetes Institute has found that combining structured exercise ...

A randomized controlled trial has shed light on the efficacy of acupuncture as a treatment for refractory irritable bowel ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Concurrently, the company also announced the approval and initiation of the ARTIST randomized controlled trial (RCT). The ALIGN-AR 2-year Follow-Up data confirmed the continued safety and efficacy ...

TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an ...

After surgery, the team analyzed and compared the tumor tissue with the healthy tissue of the same patient to find unique ...

In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...

The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 trial comparing Berubicin to Lomustine after first-line GBM therapy. The ...

The company expects to share full-topline results in early January 2025. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, showcased 2-year follow up data from ...